The use of biochemical markers of bone remodeling in multiple myeloma: a report of the International Myeloma Working Group
This report from the International Myeloma Working Group (IMWG) focuses on the multiple myeloma (MM) and its complication of lytic bone disease. Lytic bone disease is a disease that destroys the bone and can rarely be reversed. To observe lytic bone disease’s impact, “biochemical markers of bone resorption, CTX generated by matrix metalloproteinases (ICTP) and bone formation” are analyzed as bone markers. The following have increased levels in a MM patient that signify lytic bone disease and skeletal complications:
- urinary NTX
- serum CTX
- werum ICTP
Terpos E, Dimopoulos MA, Sezer O, Roodman D, Abildgaard N, Vescio R, Tosi P, Garcia-Sanz R, Davies F, Chanan-Khan A, Palumbo A, Sonneveld P, Drake MT, Harousseau JL, Anderson KC, Durie BG; International Myeloma Working Group.
Click here to view article: